LivaNova PLC Ordinary Shares LIVN
i
Market dataready · fetched 2026-11-12T16:44:58.691Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T16:43:32.972538744Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T16:44:57.877432+00:00
LivaNova PLC Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 98.74 | 63.5% | 10.1% | 84.12 | 62.6% | 8.2% |
| 25Δ | 96.99 | 61.2% | 8.5% | 85.06 | 67.3% | 7.6% |
| 30Δ | 95.24 | 59.0% | 6.8% | 86.83 | 57.9% | 5.8% |
| 35Δ | 94.07 | 59.0% | 5.9% | 88.09 | 53.3% | 4.6% |
| 40Δ | 93.00 | 59.4% | 5.2% | 89.04 | 51.6% | 3.9% |
| 45Δ | 91.96 | 58.2% | 4.4% | 89.98 | 49.8% | 3.2% |
| 50Δ | 90.96 | 55.6% | 3.6% | 90.74 | 47.9% | 2.7% |
| 55Δ | 89.96 | 53.1% | 2.9% | 91.50 | 45.9% | 2.2% |
| 60Δ | 88.96 | 54.9% | 2.5% | 92.26 | 44.0% | 1.7% |
| 65Δ | 87.97 | 56.6% | 2.2% | 93.11 | 43.6% | 1.4% |
| 70Δ | 94.00 | 44.0% | 1.1% | |||
| 75Δ | 94.90 | 44.3% | 0.9% | |||
| 80Δ | 96.38 | 45.2% | 0.6% | |||
20Δ
- Pseudo strike
- 98.74
- IV
- 63.5%
- B/E move
- 10.1%
- Pseudo strike
- 84.12
- IV
- 62.6%
- B/E move
- 8.2%
25Δ
- Pseudo strike
- 96.99
- IV
- 61.2%
- B/E move
- 8.5%
- Pseudo strike
- 85.06
- IV
- 67.3%
- B/E move
- 7.6%
30Δ
- Pseudo strike
- 95.24
- IV
- 59.0%
- B/E move
- 6.8%
- Pseudo strike
- 86.83
- IV
- 57.9%
- B/E move
- 5.8%
35Δ
- Pseudo strike
- 94.07
- IV
- 59.0%
- B/E move
- 5.9%
- Pseudo strike
- 88.09
- IV
- 53.3%
- B/E move
- 4.6%
40Δ
- Pseudo strike
- 93.00
- IV
- 59.4%
- B/E move
- 5.2%
- Pseudo strike
- 89.04
- IV
- 51.6%
- B/E move
- 3.9%
45Δ
- Pseudo strike
- 91.96
- IV
- 58.2%
- B/E move
- 4.4%
- Pseudo strike
- 89.98
- IV
- 49.8%
- B/E move
- 3.2%
50Δ
- Pseudo strike
- 90.96
- IV
- 55.6%
- B/E move
- 3.6%
- Pseudo strike
- 90.74
- IV
- 47.9%
- B/E move
- 2.7%
55Δ
- Pseudo strike
- 89.96
- IV
- 53.1%
- B/E move
- 2.9%
- Pseudo strike
- 91.50
- IV
- 45.9%
- B/E move
- 2.2%
60Δ
- Pseudo strike
- 88.96
- IV
- 54.9%
- B/E move
- 2.5%
- Pseudo strike
- 92.26
- IV
- 44.0%
- B/E move
- 1.7%
65Δ
- Pseudo strike
- 87.97
- IV
- 56.6%
- B/E move
- 2.2%
- Pseudo strike
- 93.11
- IV
- 43.6%
- B/E move
- 1.4%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 94.00
- IV
- 44.0%
- B/E move
- 1.1%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 94.90
- IV
- 44.3%
- B/E move
- 0.9%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 96.38
- IV
- 45.2%
- B/E move
- 0.6%
Options history
Table
| Date | IV (%) |
|---|---|
| 37.64% | |
| 40.70% | |
| 41.92% | |
| 40.41% | |
| 36.30% | |
| 37.96% | |
| 37.39% | |
| 37.23% | |
| 36.57% | |
| 36.81% | |
| 35.77% | |
| 35.64% | |
| 35.83% | |
| 35.30% | |
| 35.62% | |
| 38.75% | |
| 38.91% | |
| 39.63% | |
| 38.42% | |
| 38.98% | |
| 42.28% | |
| 46.40% | |
| 37.48% | |
| 38.79% | |
| 40.50% | |
| 40.50% | |
| 40.17% | |
| 40.88% | |
| 37.99% | |
| 39.12% | |
| 39.20% | |
| 38.32% | |
| 38.91% | |
| 40.46% | |
| 40.65% | |
| 41.70% | |
| 41.27% | |
| 43.84% | |
| 41.33% | |
| 46.75% | |
| 50.93% | |
| 49.92% | |
| 41.05% | |
| 40.51% | |
| 39.16% | |
| 40.26% | |
| 39.76% | |
| 42.10% | |
| 42.37% | |
| 42.23% | |
| 41.51% | |
| 40.18% | |
| 42.87% |
Medical Devices
LNSR
LENSAR, Inc., a commercial stage medical device company, is focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and…
More →LUNG
Pulmonx Corporation, a medical technology company, designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic…
More →MASS
908 Devices Inc. develops and sells measuring devices for chemical and biochemical analysis in North America, Europe, the Middle East, Africa, and Asia Pacific. The company is…
More →MBOT
Microbot Medical Inc., a preclinical medical device company, researches, designs and develops micro-robotic-assisted medical technologies targeting the minimally invasive surgery…
More →MDT
Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in…
More →MXCT
Description unavailable
More →